---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-031216"
form_type: "8-K"
ticker: "CELU"
cik: "0001752828"
company_name: "Celularity Inc"
filed_at: "2026-06-30T13:00:43+00:00"
generated_at: "2026-06-30T13:02:10.826213+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Celularity enters $1M secured loan from Barach trust; director LeVien resigns

## Summary
- Loan of $1,000,000 from Philip & Daniele Barach Family Trust (affiliated with >5% owner) at 4% interest, matures in 30 days or upon receipt of proceeds from financing.
- Loan secured by first-priority security interest in substantially all personal property; Robert J. Hariri subordinated his debt.
- Director Vincent LeVien resigned effective June 26, 2026, not due to any disagreement.

## SEC filing metadata
- accession: 0001493152-26-031216
- form_type: 8-K
- ticker: CELU
- cik: 0001752828
- company_name: Celularity Inc
- filed_at: 2026-06-30T13:00:43+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 2.03, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1752828/000149315226031216/0001493152-26-031216-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1752828/000149315226031216/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-031216
- JSON: https://secwatch.observer/filing/0001493152-26-031216.json
- Plain text: https://secwatch.observer/filing/0001493152-26-031216.txt

## Key facts
- Executive change
  Vincent LeVien resigned as Director at Celularity Inc.
  - Action: resigned
  - Role: Director
  source text: Effective June 26, 2026, Vincent LeVien resigned as a member of the Company’s Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1752828/000149315226031216/0001493152-26-031216-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.